Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MasterKey-01 of BDTX-189 in advanced solid tumors with allosteric ErbB alterations
NL-OMON52345Phase 2Completed
- Sponsor
- Black Diamond Therapeutics
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tuxobertinib in Non-hematologic malignancy, non-small cell lung cancer (NSCLC), breast cancer and 2 more, sponsored by Black Diamond Therapeutics. Started Jan 2024; status: completed.
02
Drugs
tuxobertinib
03
Conditions
Non-hematologic malignancynon-small cell lung cancer (NSCLC)breast cancerbladder cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NL-OMON52345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52345.